As senior director of global cell and gene operations, Dr. Rohin Iyer leads Marken’s advanced therapies division, managing the critical distribution of both clinical and commercial personalized medicines. Leveraging Marken’s unique CGT portfolio as its flagship premium service offering, he oversees the complex logistics across a diverse array of advanced therapeutic modalities ranging from nucleic acid therapies to CAR-T therapy, as well as the raw materials used to manufacture them.

Iyer’s leadership expertise includes over a decade in CGT development and over 15 years of hands-on laboratory work focused on stem cells, tissue engineering, immunotherapy development and regenerative medicine at large pharma organizations. With extensive experience in portfolio management, process development and bioprocess optimization in CGT and immunotherapy, he has played an instrumental role in supporting the clinical research and development of regenerative medicines. Rohin obtained his Bachelor of Applied Science and his Doctor of Philosophy in Biomedical Engineering at the University of Toronto.